Form 4: Neurocrine Biosciences CFO Sells Shares
Insider Transaction (Form 4)
Matt Abernethy, Chief Financial Officer of Neurocrine Biosciences Inc, sold 2,311 shares of common stock on September 11, 2026 for $157.20 per share.
Summary
- Grant/award: acquired 5,020 Common Stock on September 11, 2026; holds 47,828 after (Direct).
- Tax/exercise-price withholding: disposed of 2,709 Common Stock at $156.22 ($423,200) on September 11, 2026; holds 45,119 after (Direct).
- Open-market sale: disposed of 2,311 Common Stock at $157.20 ($363,285) on September 14, 2026; holds 42,808 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $363,285 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Matt Abernethy — Officer (Chief Financial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-11 | Grant/award | Common Stock | 5,020 | — | — | 47,828 |
| 2026-09-11 | Tax/exercise-price withholding | Common Stock | 2,709 | $156 | $423.2K | 45,119 |
| 2026-09-14 | Open-market sale | Common Stock | 2,311 | $157 | $363.3K | 42,808 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-11 | Grant/award (5,020 shares) |
| 2026-09-11 | Tax/exercise-price withholding (2,709 shares) |
| 2026-09-14 | Open-market sale (2,311 shares) |
Keywords
insider transaction, Form 4, NBIX, NEUROCRINE BIOSCIENCES INC, bearish, Matt Abernethy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.